openPR Logo
Press release

Yana Shneerson - Searching for EVA's traces with surrealist art and purple lips

09-09-2024 02:36 PM CET | Leisure, Entertainment, Miscellaneous

Press release from: ABNewswire

Gueney Durmus / ELITEMAG.ONE

Gueney Durmus / ELITEMAG.ONE

Image: https://www.abnewswire.com/uploads/d0eb5d148580d6c293b5b69263731565.jpg

The artist Yana Shneerson received an overwhelming response with her current series "Body Prints" and her live performances, where dramaturgy and art are closely united to draw the audience into the artist's story. The artist creates a unique atmosphere based on spontaneity and unpredictability and takes them on EVA's traces.

As one of the main representatives of surrealism, Salvador Dali is one of the most famous painters of the 20th century. His numerous works and his painting skills embody the world of the unconscious that appears in dreams in an old master style that is reminiscent of later photorealism. Unusual or opposing objects, themes, landscapes and motifs are combined and, in their constellation, form a contrast that alienates the image.

Image: https://www.abnewswire.com/uploads/b31a03e806b55b0006f5c8cb90e30334.jpg

The artist Yana Shneerson discovered her love of art as a child. Inspired by the many facets of the representation, after 10 years of private training in Dusseldorf, her own surrealism emerged, characterized by personal experiences, strong emotions, isolation and points of contact with shamanism. "The escape into art" - as the artist herself describes it - created the idea and the project "EVA's Traces", the embodiment of strength, inspiration, courage, curiosity and freedom in pictures and live shows. The central theme of the representations is and remains Eve and the fruit with which the snake tempted her - the pomegranate. With its blood-red seeds, the pomegranate is the ideal symbol for all kinds of things - temptation, fertility, passion, knowledge, curiosity or blood -

Image: https://www.abnewswire.com/uploads/7ac1fd53c023ff54db1bc4007762a891.jpgImage: https://www.abnewswire.com/uploads/ee839de9dc2eb9a345637ee9cf2019ae.jpg

Shneerson: "Curiosity drives us all! Old, young. Man and woman. And that's a good thing! With curiosity - as the key - Eve was able to open the door to knowledge. Then the demons came to light in the form of sin. In the series "EVA" I describe different emotional levels of a being who recognizes her inner facets in - or through - sin."

See more dates and infos:

https://www.instagram.com/_shneerson_?utm_source=ig_web_button_share_sheet&igsh=ZDNlZDc0MzIxNw==

Media Contact
Company Name: ELITEMAG.ONE
Contact Person: Gueney Durmus
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=yana-shneerson-searching-for-evas-traces-with-surrealist-art-and-purple-lips]
Phone: 004921192840847
Address:Wilhelmstrasse 36
City: Hamm
State: NRW
Country: Germany
Website: https://elitemag.one



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Yana Shneerson - Searching for EVA's traces with surrealist art and purple lips here

News-ID: 3649710 • Views:

More Releases from ABNewswire

Major depressive disorder Market Outlook 2034 - Clinical Trials, Market Size, Medication, Prevalence, Companies by DelveInsight
Major depressive disorder Market Outlook 2034 - Clinical Trials, Market Size, Me …
According to DelveInsight, the Major Depressive Disorder Treatment Market Size in the 7MM was approximately USD 7,165 million in 2023. Major depressive disorder Market Summary According to DelveInsight, there were ~44 million diagnosed cases of Major Depressive Disorder (MDD) across the 7MM in 2023. The US led the market, valued at ~USD 5.6 billion, projected to grow at a 4.8% CAGR through 2034. Current treatments include VRAYLAR, AUVELITY, SPRAVATO, and REXULTI, with
Short Bowel Syndrome Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies
Short Bowel Syndrome Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, F …
DelveInsight's, "Short Bowel Syndrome Pipeline Insight 2025" report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Short Bowel Syndrome pipeline landscape. It covers the Short Bowel Syndrome pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Short Bowel Syndrome therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore our latest
Sarcopenia Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies
Sarcopenia Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approva …
DelveInsight's, "Sarcopenia Pipeline Insight 2025" report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Sarcopenia pipeline landscape. It covers the Sarcopenia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Sarcopenia therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore our latest breakthroughs in Sarcopenia Research. Learn more about our
Ischemic Stroke Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies
Ischemic Stroke Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Ap …
DelveInsight's, "Ischemic Stroke Pipeline Insight, 2025" report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Ischemic Stroke pipeline landscape. It covers the Ischemic Stroke pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Ischemic Stroke pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment

All 5 Releases